Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM models. — Agnieszka Chryplewicz (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM models.
Shared by
Douglas Hanahan
Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM models.
Article
2021
en
Authors
AC
Agnieszka Chryplewicz
Douglas Hanahan
Related publications
Article
2021
Abstract 1652: Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM models
Agnieszka Chryplewicz
,
Douglas Hanahan
Article
2024
EXTH-20. EXPLORING EUPHOL’S THERAPEUTIC EFFECT IN ADULT AND PEDIATRIC BRAZILIAN HIGH-GRADE GLIOMAS PRE-CLINICAL MODELS
Mirella Baroni
,
Leticia Tshikawa
,
Raquel Megid
,
Flavia Scremim
,
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Izabela Natália Faria Gomes
,
Gustavo Ramos Teixeira
,
Luiz Fernando Lopes
,
Bruna Minniti Mançano
,
Allan Dias Polverini
,
Ismael Augusto Silva Lombardi
,
Carlos Roberto Bueno Júnior
,
Sílvia Teixeira
,
Rui L Reis
Article
2009
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
Peter Olson
,
Jun Lü
,
Hao Zhang
,
Anny Shai
,
Matthew G. H. Chun
,
Yucheng Wang
,
Steven K. Libutti
,
Eric K. Nakakura
,
Todd R. Golub
,
Douglas Hanahan
Letter
2008
Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials
Pippa Newell
,
Augusto Villanueva
,
Josep M. Llovet
Journal of Hepatology
Article
2015
Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit
Ksenya Shchors
,
Aristea Massaras
,
Douglas Hanahan
Discussion(0)
No comments yet. Be the first to comment.